------------------------------------
Dear e-druggers,
Meloxicam is claimed as a selective inhibitor of cyclooxygenase-2 enzyme
(COX-2), which is related with the biosynthesis of prostaglandins in
inflammatory events (COX-1 is mainly linked with the production of
prostaglandins linked with physiological actions like mucus production in
the stomach). Due to this selective action, it would cause fewer GI
side-effects. In Brazil, meloxicam is being advertised explicitly as a
selective inhibitor. Actualy, I am not up to date with utilization studies
involving meloxicam versus other NSAIDS in the therapy, but selective
inhibition of COX-2 seems to be an interesting approach to the treatment
of inflammatory diseases, as can be depicted from the increasing number of
articles on medicinal chemistry dealing with the synthesis and
pharmacological evaluation of such inhibitors.
Andre Reis
Rio de Janeiro - Brazil
Email: andre.reis@unikey.com.br
--
Send mail for the `E-Drug' conference to `e-drug@usa.healthnet.org'.
Mail administrative requests to `majordomo@usa.healthnet.org'.
For additional assistance, send mail to: `owner-e-drug@usa.healthnet.org'.